On July 28, GENFLEET-B declined 5.12% in regular trading, trading at HK$31.54/share, with turnover of HK$10.16 million.

On the news front, competitor Revolution Medicines announced that its oral RAS inhibitor daraxonrasib's New Drug Application (NDA) has been accepted by the FDA, based on data from its pivotal Phase III study. GENFLEET-B's core product GFH375 is also a KRAS G12D inhibitor targeting the same mechanism. The competitor's advancement to regulatory review ahead of GENFLEET-B poses direct pressure on the company's best-in-class positioning for its pipeline.

Daraxonrasib is a pan-RAS inhibitor that has demonstrated historic survival benefits in second-line pancreatic ductal adenocarcinoma (PDAC) and positive early clinical results in first-line PDAC treatment. GENFLEET-B's GFH375, while having received two Breakthrough Therapy Designations in China and Fast Track Designation from the FDA, remains in Phase III clinical trials. The competitive landscape intensification raises concerns about GENFLEET-B's timeline to market and its differentiation against an approved therapy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)